Fatty Liver Disease (AFLD/NAFLD, MASLD/MetALD) and Alcohol (consumption and alcohol use disorder)

Deep Dive

From a western clinical perspective, alcohol is both a distinct cause of steatotic liver disease and a powerful accelerator of metabolically dri... From a western clinical perspective, alcohol is both a distinct cause of steatotic liver disease and a powerful accelerator of metabolically driven fatty liver. Ethanol is oxidized to acetaldehyde and acetate, generating excess NADH that shifts hepatocyte metabolism toward fat synthesis and away from fatty acid oxidation. Induction of CYP2E1 amplifies reactive oxygen species, while acetaldehyde adducts impair mitochondrial function and protein repair. Parallel gut–liver axis disturbances increase intestinal permeability and endotoxin exposure, provoking Kupffer cell activation and cytokine cascades that drive steatohepatitis. These mechanisms converge on hepatic stellate cell activation and collagen deposition, setting the stage for fibrosis and cirrhosis. Epidemiologically, NAFLD/MASLD affects roughly a quarter to a third of adults worldwide and is rising alongside obesity and type 2 diabetes. Alcohol-related liver disease remains a leading cause of cirrhosis and liver-related mortality. When alcohol and metabolic dysfunction co-occur—now termed MetALD—risk of steatohepatitis and advanced fibrosis exceeds either exposure alone. Observational data and guidelines emphasize that for individuals with metabolic risk, there may be no reliably safe alcohol threshold for liver outcomes. Risk is further modulated by age, sex (greater susceptibility in women), and genetics (e.g., PNPLA3 I148M). Clinically, assessment includes a careful alcohol history, liver enzymes (ALT, AST, GGT), and noninvasive fibrosis stratification using FIB‑4 and elastography (FibroScan). Ultrasound detects steatosis but misses mild disease; MRI‑PDFF quantifies fat; biopsy remains the reference for grading steatohepatitis and staging fibrosis when results would change management. In ALD, severity scoring (e.g., MELD, Maddrey discriminant function) informs inpatient care for alcoholic hepatitis. Management priorities are clear: sustained abstinence is the cornerstone for ALD and prudent in MASLD with fibrosis. Nutritional rehabilitation and treatment of vitamin/mineral deficiencies are critical in ALD. For MASLD, lifestyle therapy—weight loss around 7–10%, Mediterranean-style diet, and regular aerobic plus resistance exercise—improves steatosis and cardiometabolic risk; exercise benefits even without weight loss. Pharmacotherapy options include pioglitazone or vitamin E in selected NASH patients, GLP‑1/GIP-based agents that reduce steatosis and support weight loss, and the 2024 FDA approval of resmetirom for noncirrhotic MASH with moderate-to-advanced fibrosis. Ongoing monitoring with noninvasive fibrosis tools guides intensity of care and surveillance for complications.